All Relations between Dyskinesias and dopamine

Publication Sentence Publish Date Extraction Date Species
Yinying Wang, Qian Wen, Rongsha Chen, Zhichao Gan, Xinwei Huang, Pengfei Wang, Xia Cao, Ninghui Zhao, Zhongshan Yang, Jinyuan Ya. Iron-inhibited autophagy via transcription factor ZFP27 in Parkinson's disease. Journal of cellular and molecular medicine. 2023-09-05. PMID:37668106. meanwhile, pd mice treated with deferoxamine exhibited less iron content, relieved the dyskinesia and had a significant increase in dopamine neurons and a significant decrease in \xce\xb1-synuclein. 2023-09-05 2023-09-07 mouse
Timothy J Collier, Lauren Begg, Jennifer A Stancati, Natosha M Mercado, Rhyomi C Sellnow, Ivette M Sandoval, Caryl E Sortwell, Kathy Steece-Collie. Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine. Experimental neurology. 2023-08-28. PMID:37640098. dopamine depletion associated with parkinsonism induces plastic changes in striatal medium spiny neurons (msn) that are maladaptive and associated with the emergence of the negative side-effect of standard treatment: the abnormal involuntary movements termed levodopa-induced dyskinesia (lid). 2023-08-28 2023-09-07 rat
Minhee Ku, Nam Kyung J. Exploring the prescribing trends and factors affecting initial anti-parkinsonian drug selection in Korea: A nationwide population-based cohort study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 116. 2023-08-26. PMID:37633186. parkinson's disease (pd) is a common neurodegenerative disorder typically treated with dopamine replacement therapy and dopamine agonists (das) to alleviate symptoms and minimize dyskinesia. 2023-08-26 2023-09-07 Not clear
Andrew J Flores, Mitchell J Bartlett, Blake T Seaton, Grace Samtani, Morgan R Sexauer, Nathan C Weintraub, James R Siegenthaler, Dong Lu, Michael L Heien, Frank Porreca, Scott J Sherman, Torsten Fal. Antagonism of kappa opioid receptors worsens the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion. bioRxiv : the preprint server for biology. 2023-08-14. PMID:37577558. antagonism of kappa opioid receptors worsens the development of l-dopa-induced dyskinesia in a preclinical model of moderate dopamine depletion. 2023-08-14 2023-08-16 Not clear
Sotirios Grigoriou, Elena Espa, Per Odin, Jonathan Timpka, Gustaf von Grothusen, Andreas Jakobsson, M Angela Cenc. Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration. Neuropharmacology. 2023-06-14. PMID:37315840. comparison of dyskinesia profiles after l-dopa dose challenges with or without dopamine agonist coadministration. 2023-06-14 2023-08-14 Not clear
Sotirios Grigoriou, Elena Espa, Per Odin, Jonathan Timpka, Gustaf von Grothusen, Andreas Jakobsson, M Angela Cenc. Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration. Neuropharmacology. 2023-06-14. PMID:37315840. many patients with parkinson's disease (pd) experiencing l-dopa-induced dyskinesia (lid) receive adjunct treatment with dopamine agonists, whose functional impact on lid is unknown. 2023-06-14 2023-08-14 Not clear
Xiao Fang, Meng Yuan, Fang Zhao, Aoling Yu, Qianying Lin, Shiqing Li, Huichen Li, Xinyang Wang, Yanbin Yu, Xin Wang, Qitian Lin, Chunhua Lu, Huanghao Yan. In situ continuous Dopa supply by responsive artificial enzyme for the treatment of Parkinson's disease. Nature communications. vol 14. issue 1. 2023-05-10. PMID:37160866. however, unlike the continuous and steady dopamine signaling in normal neurons, oral dopa induces dramatic fluctuations in plasma dopa levels, leading to dopa-induced dyskinesia. 2023-05-10 2023-08-14 Not clear
Haoxi Li, Nikhil M Urs, Nicole Horenstei. Computational insights into ligand-induced G protein and \\xce\\xb2-arrestin signaling of the dopamine D1 receptor. Journal of computer-aided molecular design. 2023-04-15. PMID:37060492. previous studies have suggested that therapeutic effects can be realized by targeting the \xce\xb2-arrestin signaling pathway of dopamine receptors, while overactivation of the g protein-dependent pathways leads to side effects, such as dyskinesias. 2023-04-15 2023-08-14 Not clear
Kuncheng Liu, Miaomiao Song, Shasha Gao, Lu Yao, Li Zhang, Jie Feng, Ling Wang, Rui Gao, Yong Wan. The Dynamics of Dopamine D Neuroscience bulletin. 2023-04-06. PMID:37022638. the dynamics of dopamine d l-dopa (l-3,4-dihydroxyphenylalanine)-induced dyskinesia (lid) is a debilitating complication of dopamine replacement therapy for parkinson's disease. 2023-04-06 2023-08-14 Not clear
Roger A Barker, Anders Bj\\xc3\\xb6rklun. Restorative cell and gene therapies for Parkinson's disease. Handbook of clinical neurology. vol 193. 2023-02-21. PMID:36803812. in addition, over time the nonphysiological stimulation of striatal dopamine receptors by l-dopa containing drugs leads to the genesis of l-dopa-induced dyskinesias that can become very disabling in many cases. 2023-02-21 2023-08-14 Not clear
Leslie R Wilson, Christie A Lee, Catherine F Mason, Sitora Khodjaniyazova, Kevin B Flores, David C Muddiman, Leslie A Somber. Simultaneous Measurement of Striatal Dopamine and Hydrogen Peroxide Transients Associated with L-DOPA Induced Rotation in Hemiparkinsonian Rats. ACS measurement science au. vol 2. issue 2. 2023-02-14. PMID:36785724. the neurochemical contributors to these dyskinesias are unknown; however, several lines of evidence indicate an interplay of dopamine (da) and oxidative stress. 2023-02-14 2023-08-14 rat
Elena Espa, Lu Song, Katrine Skovg\\xc3\\xa5rd, Silvia Fanni, M Angela Cenc. Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia. Movement disorders : official journal of the Movement Disorder Society. 2023-01-19. PMID:36656044. dopamine agonist cotreatment alters neuroplasticity and pharmacology of levodopa-induced dyskinesia. 2023-01-19 2023-08-14 Not clear
Chun-Lei Han, Qiao Wang, Chong Liu, Zhi-Bao Li, Ting-Ting Du, Yun-Peng Sui, Xin Zhang, Jian-Guo Zhang, Yi-Lei Xiao, Guo-En Cai, Fan-Gang Men. Transcriptome Sequencing Reveal That Rno-Rsf1_0012 Participates in Levodopa-Induced Dyskinesia in Parkinson's Disease Rats via Binding to Rno-mir-298-5p. Brain sciences. vol 12. issue 9. 2022-09-23. PMID:36138942. levodopa-induced dyskinesia (lid) is a common complication of chronic dopamine replacement therapy in the treatment of parkinson's disease (pd), and a noble cause of disability in advanced pd patients. 2022-09-23 2023-08-14 rat
Jae Hyun Ryou, Doug Hyun Han, Reeree Lee, Sun Mi Ki. Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 3. 2022-07-25. PMID:35879044. this case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. 2022-07-25 2023-08-14 Not clear
Kuan-Yin Tseng, Tung-Tai Kuo, Vicki Wang, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Lars Olson, Barry J Hoffer, Yuan-Hao Che. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. Journal of Parkinson's disease. 2022-05-23. PMID:35599497. tetrabenazine mitigates aberrant release and clearance of dopamine in the nigrostriatal system, and alleviates l-dopa-induced dyskinesia in a mouse model of parkinson's disease. 2022-05-23 2023-08-13 mouse
Carla M V Dias, Denisson A Leal, Ivani Bry. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients. The International journal of neuroscience. 2022-05-23. PMID:35603453. dopamine replacement therapy with levodopa is the gold standard treatment of parkinson's disease (pd); however long-term levodopa use is associated with abnormal involuntary movements known as levodopa induced dyskinesia (lid) in most patients. 2022-05-23 2023-08-13 Not clear
Bj\\xc3\\xb6rn Falkenburger, Theodoros Kalliakoudas, Heinz Reichman. Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). 2022-05-10. PMID:35538324. moreover, dyskinesias are considered signs of excessive dopaminergic neurotransmission in parkinson's disease, but they are typically more severe on the body side that is more strongly affected by dopamine depletion. 2022-05-10 2023-08-13 Not clear
M Angela Cenci, Katrine Skovg\\xc3\\xa5rd, Per Odi. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology. 2022-03-16. PMID:35292330. dopamine replacement therapy with l-dopa is the most efficacious symptomatic treatment for parkinson's disease, but its utility is limited by the development of motor fluctuations and abnormal involuntary movements (dyskinesia) in a majority of the patients. 2022-03-16 2023-08-13 Not clear
Samantha Smith, Jordan Sergio, Michael Coyle, Kayla Elder, Ashley Centner, Sophie Cohen, Michelle Terry, Natalie Lipari, John Glinski, Emily Wheelis, Carla Budrow, Christopher Bisho. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology. 2022-03-11. PMID:35275226. growing evidence shows that with burgeoning dopamine cell loss, neuroplasticity in the serotonin system leads to the development of l-dopa-induced dyskinesia through the unregulated uptake, conversion, and release of l-dopa-derived dopamine into the striatum. 2022-03-11 2023-08-13 rat
Cheol-Hyun Kim, Jeeyoun Jung, Young-Ung Lee, Kwang-Ho Kim, Sunny Kang, Geon-Hui Kang, Hongmin Chu, Se-Young Kim, Sangkwan Le. Comparison of Metabolites and Gut Microbes between Patients with Parkinson's Disease and Healthy Individuals-A Pilot Clinical Observational Study (STROBE Compliant). Healthcare (Basel, Switzerland). vol 10. issue 2. 2022-02-25. PMID:35206916. even if levodopa, dopamine agonists, and others are used for patients with parkinson's disease, the effect is not sustained, and side effects such as motor fluctuation and dyskinesia are more likely to appear as the dose increases. 2022-02-25 2023-08-13 Not clear